Table 1 Patients' characteristics based on TET2 and TP53 mutational status
From: Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas
Clinical Parameters | Overall N (%) | TET2 | TP53 | TET2/TP53 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
WT N (%) | Mut N (%) | P value* | WT N (%) | Mut N (%) | P value* | WT N (%) | Mut N (%) | P value* | ||
N | 49 | 18 (37) | 31 (63) | Â | 41 (84) | 8(16) | Â | 14 (29) | 35 (71) | Â |
Gender | ||||||||||
 Male | 34 (69) | 11 (32) | 23 (68) | 0.338 | 31 (91) | 3 (9) | 0.085 | 10 (29) | 24 (71) | 1.000 |
 Female | 15 (31) | 7 (46) | 8 (54) |  | 10 (67) | 5 (33) |  | 4 (27) | 11 (73) |  |
Age at diadnosis (years) | ||||||||||
 ≤ 60 | 35 (71) | 13 (37) | 22 (63) | 0.925 | 28 (80) | 7 (20) | 0.501 | 10 (29) | 25 (71) | 1.000 |
 > 60 | 14 (29) | 5 (36) | 9 (64) |  | 13 (93) | 1 (7) |  | 4 (29) | 10 (71) |  |
Diagnosis | ||||||||||
 Angioimmunoblastic T-cell lymphoma | 29 (59) | 4 (14) | 25 (86) |  < 0.001 | 28 (97) | 1 (3) | 0.003 | 4 (14) | 25 (86) | 0.028 |
 PTCL, not otherwise specified | 10 (21) | 5 (50) | 5 (50) |  | 7 (70) | 3 (30) |  | 4 (40) | 6 (60) |  |
 ALK+ anaplastic large cell lymphoma | 4 (8) | 3 (75) | 1 (25) |  | 3 (75) | 1 (25) |  | 3 (75) | 1 (25) |  |
 ALK− anaplastic large cell lymphoma | 6 (12) | 6 (100) | 0 (0) |  | 3 (50) | 3 (50) |  | 3 (50) | 3 (50) |  |
B symptoms | ||||||||||
 Negative | 23 (49) | 12 (52) | 11 (48) | 0.025 | 20 (87) | 3 (13) | 1.000 | 10 (44) | 13 (56) | 0.045 |
 Positive | 24 (51) | 5 (21) | 19 (79) |  | 21 (88) | 3 (12) |  | 4 (17) | 20 (83) |  |
LDH | ||||||||||
 Negative | 18 (37) | 10 (56) | 8 (44) | 0.037 | 15 (83) | 3 (17) | 1.000 | 9 (50) | 9 (50) | 0.011 |
 Positive | 31 (63) | 8 (26) | 23 (74) |  | 26 (84) | 5 (16) |  | 5 (16) | 26 (84) |  |
ECOG | ||||||||||
 0–1 | 44 (90) | 16 (36) | 28 (64) | 1.000 | 36 (82) | 8 (18) | 0.169 | 12 (27) | 32 (73) | 1.000 |
 2–3 | 5 (10) | 2 (40) | 3 (60) |  | 5 (100) | 0 (0) |  | 2 (40) | 3 (60) |  |
Ann Arbor stage at diagnosis | ||||||||||
 I–II | 9 (18) | 8 (89) | 1 (11) | 0.001 | 6 (67) | 3 (33) | 0.304 | 5 (56) | 4 (44) | 0.115 |
 III–IV | 40 (82) | 10 (25) | 30 (75) |  | 35 (88) | 5 (12) |  | 9 (23) | 31 (77) |  |
IPI score | ||||||||||
 0–2 | 34 (69) | 12 (35) | 22 (65) | 0.753 | 27 (79) | 7 (21) | 0.426 | 9 (27) | 25 (73) | 0.883 |
 3–5 | 15 (31) | 6 (40) | 9 (60) |  | 14 (93) | 1 (7) |  | 5 (33) | 10 (67) |  |
Ki67 | ||||||||||
 ≤ 75% | 35 (74) | 10 (29) | 25 (71) | 0.133 | 32 (91) | 3 (9) | 0.029 | 9 (26) | 26 (74) | 0.892 |
 > 75% | 12 (26) | 7 (58) | 5 (42) |  | 7 (58) | 5 (42) |  | 4 (33) | 8 (67) |  |
Extra nodal site | ||||||||||
 ≤ 1 | 33 (67) | 11 (33) | 22 (67) | 0.478 | 27 (82) | 6 (18) | 0.926 | 8 (24) | 25 (76) | 0.531 |
 > 1 | 16 (33) | 7 (44) | 9 (56) |  | 14 (87) | 2 (13) |  | 6 (37) | 10 (63) |  |